PCDHGB7 and urinary bladder carcinoma: Results showed that PCDHGB7 evaluation outperformed urine cytology in bladder cancer (82.1% vs. 34.5%), ureter cancer (78.1% vs. 34.4%), and renal pelvis cancer (90.9% vs. 22.7%) (Figure 5a), indicating this methylation‐dependent detection had higher efficiency.